Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00968071 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome (NCT00968071)

Trial Description
The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine, also known as  decitabine (Dacogen®/Otsuka America Pharmaceutical, Inc.) in combination with the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) can help to control Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS). The safety of this drug combination will also be studied.

This trial is sponsored by M.D. Anderson Cancer Center. [1]

Study Data

  • Condition:
    • Acute Myelogenous Leukemia
    • Myelodysplastic Syndrome
  • Interventions:
  • Phase: II
  • Enrollment: 71
  • Start: February 2008
  • Completion: August 2012
  • Last verified: February 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar